糖尿病患者使用二甲双胍治疗可降低胆管癌风险。
Decreased risk of cholangiocarcinoma in diabetic patients treated with metformin.
机构信息
TWS Medical Center, Bangkok, Thailand.
Department of Community Medicine, Dr. D. Y. Patil University, Pune, Maharashtra, India; Department of Medical Science, Faculty of Medicine, University of Nis, Nis, Serbia.
出版信息
J Cancer Res Ther. 2020 Dec;16(Supplement):S82-S83. doi: 10.4103/jcrt.JCRT_368_18.
BACKGROUND
Cholangiocarcinoma is an important biliary tract cancer. The high incidence of this cancer is observed in tropical Asia. Several underlying factors are mentioned for this cancer including to diabetes mellitus. The use of the antidiabetic drug, metformin, is mentioned for possibility for decreasing risk for cholangiocarcinoma.
METHODS
The work is aimed to estimate the change in risk of local people in the endemic area of cholangiocarcinoma in scenario that diabetic patients are treated with metformin in the highly endemic area of cancer in Thailand.
RESULTS
In this study, the authors estimated the change in risk of local people in the endemic area of cholangiocarcinoma in scenario that diabetic patients are treated with metformin.
CONCLUSION
The results show a slight decreased risk of cholangiocarcinoma in that scenario.
背景
胆管癌是一种重要的胆道系统癌症。这种癌症在热带亚洲的发病率很高。提到了一些导致这种癌症的潜在因素，包括糖尿病。抗糖尿病药物二甲双胍的使用被认为可能降低胆管癌的风险。
方法
这项工作旨在评估在泰国癌症高发地区，糖尿病患者使用二甲双胍治疗的情况下，当地居民在胆管癌高发地区的风险变化。
结果
在这项研究中，作者估计了在泰国癌症高发地区，糖尿病患者使用二甲双胍治疗的情况下，当地居民在胆管癌高发地区的风险变化。
结论
结果表明，在这种情况下，胆管癌的风险略有降低。
Zotero 插件